GLP-s May Lower Cancer Risk In A Surprising Way, Study Finds

GLP-1s like semaglutide and tirzepatide have dominated health headlines for their weight loss results. Researchers, though, are increasingly asking a different question: what else can these medications do?

GLP-1 receptor agonists work by mimicking a hormone your body already makes, one that's released by the gut after you eat and helps regulate blood sugar, appetite, and metabolism. Pharmaceutical versions amplify that system, and their effects appear to reach well beyond the scale.

For this study, researchers investigated whether GLP-1 use lowers the risk of obesity-related cancers in people with obesity who don't have diabetes.

Earlier research had suggested a link between GLP-1 use and lower cancer risk, but those studies included people with both diabetes. However, in those studies, a reduced risk from the medication versus a reduced risk from improvements in diabetes management.

One notable exception: the association was not seen in the Black race subgroup, a finding the researchers flag as needing further investigation

The authors are careful to note that this is still an association, not proof of cause and effect, and that longer-term studies are needed.

To understand why GLP-1 medications might influence cancer risk, it helps to understand how excess body fat creates conditions in the body that can promote cancer development.

Carrying excess weight (particularly around the abdomen) is linked to higher levels of insulin, chronic low-grade inflammation, and hormonal imbalances. They create a biological environment that can encourage abnormal cell growth. Research has linked excess body weight1 to at least 13 types of cancer, including endometrial, colorectal, postmenopausal breast, ovarian, kidney, and pancreatic cancers.

GLP-1 receptor agonists do more than suppress appetite. These medications interact with receptors found throughout the body (in the gut, kidneys, heart, blood vessels, and brain). This is part of why researchers believe their effects extend well beyond weight loss.

When it comes to cancer risk specifically, the mechanisms are still being studied.

But researchers point to several plausible explanations. GLP-1 medications improve how the body responds to insulin and help reduce chronic inflammation, two of the main biological drivers of obesity-related cancer risk.

GLP-1 medications work best as part of a comprehensive health plan. is critical — a meaningful portion of weight lost on these medications can come from lean muscle mass, particularly when appetite drops and protein intake falls with it.

Prioritizing protein at each meal and maintaining a consistent resistance training routine are among the most important steps you can take to protect muscle health and support long-term metabolic function.

This large observational study found that obese adults without diabetes who used GLP-1 medications had a substantially lower short-term risk of developing obesity-related cancers compared with similar patients who received diet and exercise counseling alone.